Law & Regulation
DEA Places Six Cannabinoids In Temporary Schedule 1
The Administrator of the Drug Enforcement Administration (DEA) has issued a temporary order to schedule six synthetic cannabinoids in schedule I under…
The Administrator of the Drug Enforcement Administration (DEA) has issued a temporary order to schedule six synthetic cannabinoids in schedule I under the Controlled Substances Act. The DEA said the action was based on a finding by the Administrator that the placement of these six substances in schedule I was necessary to avoid imminent hazard to public safety. The temporary order begins today and is effective until December 12, 2025.
The products are sold in gas stations, convenience stores, and smoke shops. They are sold as herbal incense and promoted as a legal alternative to cannabis.
The cannabinoids are:
•Methyl 3,3-dimethyl-2-(1-(pent-4- en-1-yl)-1H-indazole-3- carboxamido)butanoate (Other name: MDMB–4en–PINACA)
•Methyl 2-[[1-(4-fluorobutyl)indole- 3-carbonyl]amino]-3,3-dimethyl- butanoate (Other names: 4F–MDMB– BUTICA; 4F–MDMB–BICA)
•N-(1-amino-3,3-dimethyl-1- oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H- indazole-3-carboxamide (Other name: ADB–4en–PINACA)
• 5-Pentyl-2-(2-phenylpropan-2- yl)pyrido[4,3-b]indol-1-one (Other name: CUMYL–PEGACLONE; SGT– 151)
• Ethyl 2-[[1-(5-fluoropentyl)indole-3- carbonyl]amino]-3,3-dimethyl-butanoate (Other names: 5F–EDMB–PICA; 5F– EDMB–2201
•Methyl 2-(1-(4-fluorobenzyl)-1H- indole-3-carboxamido)-3-methyl butanoate (Other name: MMB–FUBICA).
Synthetic Cannabinoids
The notice described synthetic cannabinoids as substances that are synthesized in laboratories that mimic delta-9- tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis. The DEA said that from 2009, abuse of SCs has escalated in the United States noting recent hospital reports, and said the products are negatively impacting communities. They also state that there are no medical uses for these products.
The DEA said that emergency room situations involving these compounds have included seizures, sudden collapse, involuntary muscle spasms, jerking movements, catatonia, and increased violence.
Multiple deaths have been reported involving MDMB- 4en-PINACA, 4F-MDMB-BUTICA, and CUMYL-PEGACLONE. In addition, all six SCs have been seized by law enforcement in the United States. Based on the pharmacological similarities between MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL- PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA and other schedule I SCs, these six SCs are likely to produce signs of addiction and withdrawal.
These products typically come from China in bulk powder form and are smuggled via common carrier into the United States and find their way to clandestine designer drug product manufacturing operations located in residential neighborhoods, garages, warehouses, and other similar destinations throughout the country. The producers then spray or mix the SCs with plant material for consumers to smoke with a pipe or rolled into a joint.
Next Steps
The new order states that if sellers don’t have a license to sell these Schedule 1 drugs, they need to surrender these products. If this order is extended or made permanent, the DEA said it will publish a document in the Federal Register.
The post DEA Places Six Cannabinoids In Temporary Schedule 1 appeared first on Green Market Report.
controlled substances act psychoactive-
Psychedelics1 week ago
Optimi Health Provides Corporate Update
-
Law & Regulation1 week ago
Horizons talk shifts from investors to insurance
-
Law & Regulation1 week ago
DEA psychedelics ban hearing halted by lawsuit
-
Law & Regulation6 days ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics5 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
-
Psychedelics4 days ago
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
-
Law & Regulation6 days ago
AbbVie, Gilgamesh Pharmaceuticals enter psychiatric drug deal
-
Psychedelics5 days ago
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine